Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous ...

The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) as a neoadjuvant treatment and then continued ...

Pembrolizumab plus platinum-based chemotherapy has demonstrated efficacy as first-line treatment for advanced penile cancer in a phase 2 trial. The results were published in JAMA Oncology.

Adjuvant pembrolizumab improved recurrence-free survival among patients with resected Merkel cell carcinoma, but not significantly.

Adding EV and pembrolizumab to surgical treatment can improve outcomes in MIBC patients who are ineligible for cisplatin, data suggest.

The addition of an investigational therapeutic cancer vaccine to first-line pembrolizumab exhibited activity among patients ...

Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...

Nicoletta Colombo, MD, PhD, of the University of Milan-Bicocca, discussed the rationale behind paclitaxel with bevacizumab ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...